Kilpatrick Townsend’s Silicon Valley-based start-up team advised the founders of Editas Medicine in the biotech start-up’s $43 million Series A Financing. In a trend setting transaction, venture firms Polaris Partners, Third Rock Ventures, Flagship Ventures and the Partners Innovation Fund invited five of the most prominent research scientists in the field of genomics from MIT, Harvard, the Howard Hughes Medical Institute and the University of California in Berkeley to form a company which they would fund. The money invested will fund the collaborative research and development by this world-class team of scientists as they seek to revolutionize the treatment of genetic disorders by developing a simple, precise and inexpensive method of ‘editing out’ abnormalities in genes in human cells.

Experience Center

Match our Experience to Your Needs

View All Case Studies

Experience Highlights

Researched and advised commercial lending company of open source implications
Advised a commercial lending company on open source implications of new product release. more
Domain name dispute actions for multiple representative clients
The firm represented numerous trademark owners in domain name dispute actions arising under the Anti-Cybersquatting Consumer Protection Act and under more
Employment litigation for a Fortune 500 retail company
Represented a Fortune 500 retail company in a former employee's discrimination lawsuit, which alleged hostile work environment, retaliation, more
Project counsel for a major governmental entity regarding WRCT tunnel
Served as project counsel for a major governmental entity on a 6.9 mile sewer/CSO tunnel in Northern Kentucky. We assisted with contract documents, more